Nathan Theodore Connell, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| von Willebrand Diseases | 15 | 2022 | 118 | 5.280 |
Why?
|
| Hematology | 5 | 2021 | 200 | 1.220 |
Why?
|
| Thrombosis | 5 | 2021 | 2852 | 1.210 |
Why?
|
| Hemophilia A | 4 | 2022 | 349 | 1.160 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 3 | 2021 | 222 | 1.140 |
Why?
|
| Hematologic Diseases | 2 | 2020 | 494 | 1.080 |
Why?
|
| Heparin | 4 | 2021 | 1636 | 1.030 |
Why?
|
| Venous Thromboembolism | 5 | 2021 | 1573 | 1.020 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2021 | 18 | 0.880 |
Why?
|
| Anticoagulants | 7 | 2021 | 4368 | 0.850 |
Why?
|
| Hemoglobinuria, Paroxysmal | 2 | 2019 | 100 | 0.840 |
Why?
|
| von Willebrand Factor | 10 | 2022 | 668 | 0.790 |
Why?
|
| Dalteparin | 1 | 2019 | 42 | 0.760 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2020 | 182 | 0.720 |
Why?
|
| Plasmacytoma | 1 | 2019 | 185 | 0.690 |
Why?
|
| Oxazines | 1 | 2019 | 301 | 0.640 |
Why?
|
| Hemorrhage | 8 | 2022 | 3273 | 0.620 |
Why?
|
| Pyridines | 2 | 2019 | 2867 | 0.620 |
Why?
|
| Complement System Proteins | 1 | 2020 | 835 | 0.590 |
Why?
|
| Skull Base Neoplasms | 1 | 2019 | 277 | 0.560 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2016 | 328 | 0.540 |
Why?
|
| Plasma Exchange | 1 | 2015 | 153 | 0.530 |
Why?
|
| Vitamin K | 1 | 2016 | 284 | 0.520 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2015 | 134 | 0.510 |
Why?
|
| ADAM Proteins | 1 | 2015 | 271 | 0.500 |
Why?
|
| Perioperative Care | 1 | 2021 | 1070 | 0.480 |
Why?
|
| Thrombocytopenia | 3 | 2021 | 1140 | 0.470 |
Why?
|
| Prednisone | 2 | 2018 | 1549 | 0.440 |
Why?
|
| Menorrhagia | 2 | 2022 | 57 | 0.440 |
Why?
|
| Thiazoles | 1 | 2019 | 1515 | 0.440 |
Why?
|
| Hemostasis | 4 | 2022 | 452 | 0.430 |
Why?
|
| Splenosis | 1 | 2011 | 4 | 0.430 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 5258 | 0.420 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2010 | 19 | 0.420 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2011 | 54 | 0.420 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2010 | 30 | 0.420 |
Why?
|
| Splenic Diseases | 1 | 2011 | 94 | 0.400 |
Why?
|
| Blood Transfusion | 1 | 2016 | 1258 | 0.390 |
Why?
|
| Polysaccharides | 1 | 2016 | 993 | 0.380 |
Why?
|
| Tranexamic Acid | 2 | 2022 | 149 | 0.380 |
Why?
|
| Dexamethasone | 2 | 2016 | 1949 | 0.360 |
Why?
|
| Methylprednisolone | 1 | 2010 | 400 | 0.360 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 4849 | 0.340 |
Why?
|
| Liver Abscess | 1 | 2007 | 77 | 0.330 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2020 | 183 | 0.320 |
Why?
|
| Klebsiella Infections | 1 | 2007 | 148 | 0.310 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 652 | 0.310 |
Why?
|
| Warfarin | 1 | 2015 | 1457 | 0.300 |
Why?
|
| Cysts | 1 | 2011 | 638 | 0.300 |
Why?
|
| Pulmonary Fibrosis | 1 | 2010 | 549 | 0.290 |
Why?
|
| Klebsiella pneumoniae | 1 | 2007 | 280 | 0.280 |
Why?
|
| Humans | 58 | 2023 | 715118 | 0.280 |
Why?
|
| Cochlear Implants | 2 | 2021 | 300 | 0.270 |
Why?
|
| Endophthalmitis | 1 | 2007 | 261 | 0.270 |
Why?
|
| Markov Chains | 2 | 2019 | 985 | 0.260 |
Why?
|
| Partial Thromboplastin Time | 2 | 2021 | 211 | 0.250 |
Why?
|
| Physicians | 1 | 2021 | 4340 | 0.250 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2022 | 6 | 0.230 |
Why?
|
| Primary Health Care | 2 | 2016 | 4528 | 0.230 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2022 | 5 | 0.230 |
Why?
|
| Factor XI Deficiency | 1 | 2021 | 18 | 0.230 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 4208 | 0.220 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2019 | 1610 | 0.220 |
Why?
|
| Blood Platelet Disorders | 1 | 2021 | 59 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 5141 | 0.210 |
Why?
|
| Glucocorticoids | 1 | 2010 | 2109 | 0.210 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 150 | 0.200 |
Why?
|
| Cochlear Implantation | 2 | 2021 | 276 | 0.190 |
Why?
|
| Hemostatics | 1 | 2022 | 228 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 20397 | 0.190 |
Why?
|
| Thrombocythemia, Essential | 1 | 2020 | 102 | 0.190 |
Why?
|
| Neuroma, Acoustic | 1 | 2023 | 441 | 0.180 |
Why?
|
| Abortion, Spontaneous | 2 | 2020 | 467 | 0.180 |
Why?
|
| Remote Consultation | 1 | 2021 | 251 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2021 | 282 | 0.180 |
Why?
|
| Desensitization, Immunologic | 2 | 2021 | 490 | 0.180 |
Why?
|
| Dermatofibrosarcoma | 1 | 2018 | 60 | 0.170 |
Why?
|
| Factor Xa | 1 | 2019 | 162 | 0.170 |
Why?
|
| Postpartum Hemorrhage | 1 | 2022 | 243 | 0.170 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 331 | 0.170 |
Why?
|
| Helicobacter Infections | 1 | 2021 | 335 | 0.170 |
Why?
|
| Heart Transplantation | 1 | 2010 | 3081 | 0.160 |
Why?
|
| Speech Perception | 1 | 2021 | 439 | 0.160 |
Why?
|
| Live Birth | 1 | 2020 | 459 | 0.160 |
Why?
|
| Sepsis | 1 | 2011 | 2474 | 0.160 |
Why?
|
| Morpholines | 1 | 2019 | 571 | 0.140 |
Why?
|
| Hematologic Tests | 1 | 2016 | 233 | 0.140 |
Why?
|
| Bone Marrow Diseases | 1 | 2017 | 236 | 0.140 |
Why?
|
| Medical Oncology | 2 | 2019 | 2114 | 0.140 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 235 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2021 | 935 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2019 | 544 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 812 | 0.130 |
Why?
|
| Female | 21 | 2022 | 377328 | 0.130 |
Why?
|
| Cochlea | 2 | 2021 | 784 | 0.130 |
Why?
|
| Rhode Island | 1 | 2015 | 360 | 0.130 |
Why?
|
| Neoplasms | 3 | 2019 | 20515 | 0.130 |
Why?
|
| Mentors | 1 | 2019 | 612 | 0.130 |
Why?
|
| Pregnancy | 5 | 2022 | 27180 | 0.130 |
Why?
|
| Pyridones | 1 | 2019 | 688 | 0.130 |
Why?
|
| Internationality | 1 | 2019 | 995 | 0.130 |
Why?
|
| Aging | 2 | 2022 | 8368 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 963 | 0.120 |
Why?
|
| Career Choice | 1 | 2019 | 744 | 0.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2021 | 868 | 0.110 |
Why?
|
| Leukocytes | 1 | 2021 | 2102 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 34394 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 993 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 990 | 0.110 |
Why?
|
| Adult | 15 | 2021 | 212128 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 7480 | 0.100 |
Why?
|
| Blood Coagulation Tests | 2 | 2022 | 268 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 1240 | 0.100 |
Why?
|
| Oseltamivir | 1 | 2010 | 70 | 0.100 |
Why?
|
| Intensive Care Units | 2 | 2021 | 3441 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2021 | 2474 | 0.100 |
Why?
|
| Specialization | 1 | 2015 | 792 | 0.100 |
Why?
|
| Mastectomy | 1 | 2018 | 1703 | 0.100 |
Why?
|
| Factor VIII | 2 | 2022 | 345 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2022 | 4639 | 0.090 |
Why?
|
| Education, Medical | 1 | 2021 | 1688 | 0.090 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 1834 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1573 | 0.090 |
Why?
|
| Azacitidine | 1 | 2010 | 298 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 6858 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2019 | 1974 | 0.090 |
Why?
|
| Platelet Count | 2 | 2021 | 795 | 0.080 |
Why?
|
| Internal Medicine | 1 | 2015 | 1006 | 0.080 |
Why?
|
| Neutrophils | 1 | 2021 | 3850 | 0.080 |
Why?
|
| Physician's Role | 1 | 2015 | 978 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2015 | 2509 | 0.080 |
Why?
|
| Antidotes | 2 | 2019 | 138 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 2395 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2018 | 2333 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2015 | 3963 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 2341 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1742 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3562 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 2695 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2019 | 2969 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 58503 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 468 | 0.070 |
Why?
|
| Male | 12 | 2023 | 351080 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 773 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 13267 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 2010 | 845 | 0.070 |
Why?
|
| Risk Factors | 4 | 2020 | 70705 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 879 | 0.070 |
Why?
|
| Spleen | 1 | 2011 | 2476 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18789 | 0.060 |
Why?
|
| Cardiology | 1 | 2015 | 1651 | 0.060 |
Why?
|
| Anxiety | 1 | 2018 | 3898 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2018 | 5028 | 0.060 |
Why?
|
| Models, Biological | 1 | 2020 | 9893 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2022 | 98 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 5482 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3158 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3276 | 0.050 |
Why?
|
| Epistaxis | 1 | 2022 | 108 | 0.050 |
Why?
|
| Middle Aged | 9 | 2021 | 214868 | 0.050 |
Why?
|
| Prothrombin Time | 1 | 2020 | 123 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 293 | 0.050 |
Why?
|
| Facial Nerve | 1 | 2023 | 277 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6538 | 0.050 |
Why?
|
| United States | 5 | 2019 | 67666 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2021 | 420 | 0.050 |
Why?
|
| Influenza, Human | 1 | 2010 | 1378 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 5312 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2021 | 430 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 443 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 8998 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2010 | 1699 | 0.050 |
Why?
|
| Asia | 1 | 2021 | 639 | 0.040 |
Why?
|
| Biopsy | 1 | 2010 | 6750 | 0.040 |
Why?
|
| Depression | 1 | 2018 | 7256 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 129 | 0.040 |
Why?
|
| Lactation Disorders | 1 | 2017 | 17 | 0.040 |
Why?
|
| Enoxaparin | 1 | 2020 | 361 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2010 | 2794 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2019 | 148 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 445 | 0.040 |
Why?
|
| Nurse-Patient Relations | 1 | 2018 | 103 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 579 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 690 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 997 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2022 | 1705 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2023 | 72253 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2021 | 1677 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2020 | 915 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 23510 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2017 | 604 | 0.040 |
Why?
|
| Fetal Death | 1 | 2017 | 456 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 356 | 0.030 |
Why?
|
| Melphalan | 1 | 2016 | 383 | 0.030 |
Why?
|
| Aged | 5 | 2021 | 162672 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 29441 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 23281 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1743 | 0.030 |
Why?
|
| Antithrombins | 1 | 2016 | 297 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2019 | 1110 | 0.030 |
Why?
|
| Telomerase | 1 | 2017 | 744 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2016 | 801 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2017 | 756 | 0.030 |
Why?
|
| Leiomyoma | 1 | 2016 | 688 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 20058 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2023 | 2032 | 0.030 |
Why?
|
| Drug Costs | 1 | 2019 | 1154 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2016 | 2189 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2023 | 62186 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 2530 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3707 | 0.020 |
Why?
|
| Caregivers | 1 | 2019 | 1905 | 0.020 |
Why?
|
| Critical Illness | 1 | 2021 | 2531 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2023 | 15097 | 0.020 |
Why?
|
| Motivation | 1 | 2018 | 1893 | 0.020 |
Why?
|
| RNA | 1 | 2017 | 2709 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2020 | 5943 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2022 | 9022 | 0.020 |
Why?
|
| Communication | 1 | 2021 | 3498 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 13731 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 14877 | 0.020 |
Why?
|
| Mass Screening | 1 | 2021 | 5204 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 11284 | 0.020 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2018 | 2126 | 0.020 |
Why?
|
| Logistic Models | 1 | 2019 | 13594 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8912 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 13302 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 8016 | 0.010 |
Why?
|
| Hospitalization | 1 | 2022 | 9718 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2018 | 4168 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 7045 | 0.010 |
Why?
|
| Medicare | 1 | 2019 | 5759 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 16011 | 0.010 |
Why?
|
| Incidence | 1 | 2020 | 20596 | 0.010 |
Why?
|
| Animals | 2 | 2011 | 170733 | 0.010 |
Why?
|
| Registries | 1 | 2017 | 8090 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 7212 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 39804 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 4515 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 51182 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29167 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 24645 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39285 | 0.010 |
Why?
|
| Child | 1 | 2021 | 74147 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 85001 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 56155 | 0.010 |
Why?
|